InvestorTalk Alert: Andre Larente from Diagnos Inc. to host on Tuesday, October 7, 2025

written by InvestorNews | October 6, 2025
InvestorNews.com is pleased to announce an upcoming InvestorTalk scheduled for tomorrow, Tuesday, October 7, at 9 AM EST, featuring Andre Larente, President, CEO, and Director, DIAGNOS Inc. (TSXV: ADK | OTCQB: DGNOF). To participate in this engaging discussion, please click here

DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA's image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients.

In preparation for tomorrow's InvestorTalk, here are some recent news releases from DIAGNOS for your review, which are listed below:

- September 25, 2025 – DIAGNOS Announces Voting Results of Meeting of Shareholders – click here
- September 5, 2025 – DIAGNOS Announces Closing of Private Placement – click here
- September 3, 2025 – DIAGNOS Announces Private Placement – click here

- August 15, 2025 – DIAGNOS to Extend Stock Warrants Exercise Period – click here
- August 13, 2025 – DIAGNOS Announces Extension of Stock Warrants Exercise Period https://bit.ly/3JfR4WM
- July 16, 2025 – DIAGNOS Files FDA Pre-Submission for its CARA System: Strategic Entry into the U.S. Optometry Market with Support from ORA LLC https://bit.ly/46NZNcf

We found the July 16 news release titled, "*DIAGNOS Files FDA Pre-Submission for its CARA System: Strategic Entry into the U.S. Optometry Market with Support from ORA LLC*" particularly noteworthy and here are 5 key data points from it:

- **FDA Pre-Submission Filed for CARA System –** DIAGNOS Inc. has formally submitted a Pre-Submission (Q-sub) to the U.S. Food and Drug Administration (FDA) for its flagship CARA System, marking the company's first step toward obtaining regulatory clearance for commercial deployment in the U.S. optometry market.
- **AI-Driven Retinal Disease Detection –** The cloud-based CARA platform uses artificial intelligence to assist optometrists in detecting Diabetic Retinopathy (DR), Hypertensive Retinopathy (HR), Age-Related Macular Degeneration (ARMD), and other retinal or vascular anomalies.
- **Large U.S. Market Opportunity –** The U.S. has approximately 49,300 practicing optometrists performing an estimated 88 million eye exams annually, presenting a significant addressable market for DIAGNOS' AI-assisted diagnostic tool.
- **Extensive Global Dataset –** CARA's algorithms are trained on data from over 450,000 patients across 16 countries, enhancing the system's robustness, reliability, and adaptability across diverse populations and clinical

environments.

- **Strategic Support and Vision –** The FDA pre-submission was completed with regulatory support from ORA LLC, a recognized ophthalmic regulatory consultancy. DIAGNOS emphasizes that CARA's design streamlines workflows and empowers optometrists to focus more on patient care and early detection of systemic diseases through microcirculation analysis.

For more information on Diagnos Inc., click here

For more information on the InvestorTalk pre-market series, go to InvestorTalk.com.